Related Experiment Video
Updated: Dec 29, 2025
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
17.8K
MicroRNAs in venous thrombo-embolism.
Anju Angelina Hembrom1, Swati Srivastava1, Iti Garg1
1Defence Institute of Physiology and Allied Sciences (DIPAS), Defence Research and Development Organisation (DRDO), Lucknow Road, Timarpur, Delhi 110054, India.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|February 5, 2020
Summary
MicroRNAs (miRNAs) show promise as diagnostic biomarkers for venous thrombo-embolism (VTE). Further research is needed to confirm their role in VTE diagnosis and potential therapeutic applications.
Area of Science:
- Biochemistry
- Molecular Biology
- Genetics
Background:
- Venous thrombo-embolism (VTE) is a leading preventable cause of death, with current diagnostic markers like D-dimer lacking sensitivity and specificity.
- Virchow's triad identifies stasis, hypercoagulability, and endothelial dysfunction as key VTE factors.
- MicroRNAs (miRNAs), small non-coding RNAs regulating gene expression, are implicated in various cardiovascular and complex diseases.
Purpose of the Study:
- To review recent studies on the role of miRNAs in the pathogenesis of complex diseases, with a focus on venous thrombosis.
- To explore the potential of miRNAs as sensitive and specific diagnostic biomarkers for VTE.
- To consolidate information on miRNAs linked to VTE for potential diagnostic and therapeutic applications.
Main Methods:
- Systematic review of existing literature on miRNAs and their association with VTE.
- Analysis of studies investigating miRNA differential expression patterns in relation to VTE symptoms.
- Consolidation of findings to assess the diagnostic and therapeutic potential of miRNAs in VTE.
Main Results:
- Circulating miRNAs have demonstrated potential as clinical diagnostic biomarkers across various diseases.
- Differential expression of specific miRNAs correlates strongly with the pathological symptoms of diseases, including VTE.
- Consolidated miRNA data suggests a potential role in identifying accurate diagnostic markers for thrombosis.
Conclusions:
- MicroRNAs play a significant role in the pathogenesis of complex diseases, including venous thrombosis.
- Further extensive research and confirmatory experiments are required to establish miRNAs as reliable biomarkers for VTE diagnosis.
- MiRNAs may also hold potential for future VTE therapeutic strategies.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
210
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
210
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
233
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
233
01:29Venous Thrombosis III: Interprofessional Care
231
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
231
01:22MicroRNAs
23.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
01:22MicroRNAs
3.6K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.6K
01:30Venous Thrombosis IV: Nursing Management
157
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
157